Omnicare (OCR) 97.90 $OCR
CVS Health Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount
PR Newswire - Tue May 31, 7:00AM CDT
CVS Health Corporation ("CVS Health", NYSE: CVS) announced today the early tender results, applicable Reference Yields and consideration payable in connection with its previously announced cash tender offers (the "Tender Offers"
for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the "Any and All Notes" and (2) up to $1,500,000,000 aggregate principal amount of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.750% Senior Notes due 2041, the 5.00% Senior Notes due 2024 (the "Omnicare 2024 Notes" issued by its wholly-owned subsidiary, Omnicare, Inc. ("Omnicare", the 4.75% Senior Notes due 2022 (together with the Omnicare 2024 Notes, the "Omnicare Notes" issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Notes".
OCR: 97.90 (-0.02), CVS: 95.78 (-0.89)
Global Intravenous Solutions Market Growth of 5.79% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Baxter, Terumo, Omnicare - Research and Markets
BusinessWire - Tue May 31, 3:58AM CDT
Research and Markets has announced the addition of the "Global Intravenous Solutions Market 2016-2020" report to their offering.
OCR: 97.90 (-0.02)
CVS Health Corporation Announces Cash Tender Offers for Certain Outstanding Notes
PR Newswire - Mon May 16, 7:45AM CDT
CVS Health Corporation ("CVS Health", NYSE: CVS) announced today that it has commenced cash tender offers (the "Tender Offers" for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the "Any and All Notes" and (2) up to $1,500,000,000 aggregate principal amount (the "Maximum Tender Offer Amount" of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.750% Senior Notes due 2041, the 5.00% Senior Notes due 2024 (the "Omnicare 2024 Notes" issued by its wholly-owned subsidiary, Omnicare, Inc. ("Omnicare", the 4.75% Senior Notes due 2022 (the "Omnicare 2022 Notes", and together with the Omnicare 2024 Notes, the "Omnicare Notes" issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Notes". The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 16, 2016 (as amended or supplemented from time to time, the "Offer to Purchase" and related Letter of Transmittal (the "Letter of Transmittal". The Tender Offers are open to all registered holders (individually, a "Holder" and collectively, the "Holders" of the Notes. The purpose of the Tender Offers is to refinance a portion of CVS Health's outstanding indebtedness.
OCR: 97.90 (-0.02), CVS: 95.78 (-0.89)
Ventas Board Appoints James D. Shelton as Presiding Director
BusinessWire - Tue May 10, 6:56PM CDT
Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company" said today its Board of Directors (the "Board" has appointed James D. ("Denny" Shelton to serve as the Company's independent presiding director. Douglas Crocker II, who served the Company as independent presiding director for 13 years, has retired from the Board in connection with the Company's retirement policy.
OCR: 97.90 (-0.02), EVHC: 27.18 (-0.47), VTR: 69.34 (+0.76)
Bass, Berry & Sims Releases Annual Review of 2015 Securities and Shareholder Litigation
BusinessWire - Thu Mar 10, 10:47AM CST
Bass, Berry & Sims PLC announces the release of the "Securities & Shareholder Litigation: 2015 Year-End Review," the firm's annual report on the most important trends and developments in securities and corporate governance matters affecting companies and their officers and directors. The report provides analysis of significant developments in corporate and securities law in 2015, including the establishment of the Tennessee Business Court, the new rulings applying the U.S. Supreme Court's Omnicare decision, merger and acquisition lawsuits and liability, and major cases out of the Sixth Circuit. Written with an eye to lawyers and non-lawyers alike, the report also offers practical guidance for officers, directors, and general counsel as they navigate these issues going forward. Download the full 2015 Securities and Shareholder Litigation Report here.
OCR: 97.90 (-0.02)
Fitch: Publix, AmerisourceBergen Deal Underscores Power of Scale
BusinessWire - Thu Feb 04, 12:51PM CST
The largest drug sourcing entities and major U.S. drug distributors continue to prove the benefits of their unmatched scale as they win increasingly comprehensive distribution contracts with pharmacy chains in the U.S., according to Fitch Ratings. This trend is highlighted by Thursday's announced agreement between AmerisourceBergen (ABC) and Publix.
ABC: 76.41 (-0.05), OCR: 97.90 (-0.02)
EXL Announces Appointment of Nitin Sahney to Board of Directors
GlobeNewswire - Tue Dec 15, 5:00AM CST
EXL (NASDAQ:EXLS), a leading business process solutions company, today announced that Nitin Sahney, the former President and CEO of Omnicare Inc. and a seasoned executive in the healthcare industry, has been appointed to the Company's Board of Directors as an independent director effective January 1, 2016. The appointment of Nitin Sahney follows the decision by Dr. Mohanbir Sawhney to retire from the Board of Directors effective December 31, 2015 following ten years of dedicated service.
EXLS: 51.30 (+0.01), OCR: 97.90 (-0.02)
RBNZ Cuts, But Could It Be the Last One?
Chuck Butler - Daily Reckoning - Thu Dec 10, 10:58AM CST
This post RBNZ Cuts, But Could It Be the Last One? appeared first on Daily Reckoning . The RBNZ cuts rates, while Governor Wheeler hints that this could be the last rate cut of this cycle. How are the currencies being affected? Chuck Butler...
OCR: 97.90 (-0.02), RBA: 33.42 (-0.08)
Omnicare Up 53.3% Since SmarTrend Uptrend Call (OCR)
Comtex SmarTrend(R) - Mon Nov 30, 10:21AM CST
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 14 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
Omnicare Has Returned 53.3% Since SmarTrend Recommendation (OCR)
Comtex SmarTrend(R) - Mon Nov 23, 9:22AM CST
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 13 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
Shares of OCR Up 53.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 13, 4:51PM CST
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 13 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
53.3% Return Seen to Date on SmarTrend Omnicare Call (OCR)
Comtex SmarTrend(R) - Fri Oct 30, 10:13AM CDT
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 12 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
Uptrend Call Working As Omnicare Stock Rises 53.3% (OCR)
Comtex SmarTrend(R) - Thu Oct 22, 4:44PM CDT
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 12 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
The ECB, and Draghi Have the Spotlight
Chuck Butler - Daily Reckoning - Thu Oct 22, 9:24AM CDT
This post The ECB, and Draghi Have the Spotlight appeared first on Daily Reckoning . The markets have fired a warning shot across the ECB's bow, and threatened to push the euro higher if the ECB doesn't add more stimulus. Oh the Humanity! Chuck...
OCR: 97.90 (-0.02), BOE: 11.77 (-0.37)
CVS Health Corporation Announces Expiration of Exchange Offers and Consent Solicitations
PR Newswire - Wed Oct 21, 9:55AM CDT
CVS Health Corporation ("CVS Health", NYSE: CVS) announced today the expiration at 11:59 p.m., New York City time, on October 20, 2015 (the "Expiration Date", of its previously announced (A) private exchange offers ("Exchange Offers" to Eligible Holders (as defined below) to exchange new 4.75% Senior Notes due 2022 (the "New CVS Health 2022 Notes" and new 5.00% Senior Notes due 2024 (the "New CVS Health 2024 Notes" and, together with the New CVS Health 2022 Notes, the "New CVS Health Notes", in each case issued by CVS Health, and cash payments for the 4.75% Senior Notes due 2022 (the "Existing Omnicare 2022 Notes" and the 5.00% Senior Notes due 2024 (the "Existing Omnicare 2024 Notes" and, together with the Existing Omnicare 2022 Notes, the "Existing Omnicare Notes", in each case issued by Omnicare, Inc. ("Omnicare", which was recently acquired by CVS Health, and (
solicitation of consents (the "Consent Solicitations" from Eligible Holders of Existing Omnicare Notes to proposed amendments that would eliminate substantially all restrictive covenants and certain events of default and other provisions of the indentures under which such Existing Omnicare Notes were issued (the "Proposed Amendments".
OCR: 97.90 (-0.02), CVS: 95.78 (-0.89)
Tailwind Capital Expands its Healthcare Team
BusinessWire - Wed Oct 21, 7:00AM CDT
Tailwind Capital, a leading middle market private equity firm investing in growth-oriented companies in targeted sectors in healthcare, business and communications services, announced that it has recently added Eran Broshy and Cliff Gookin as Operating Executives.
OCR: 97.90 (-0.02)
Omnicare Shares Up 53.3% Since SmarTrend's Buy Recommendation (OCR)
Comtex SmarTrend(R) - Thu Oct 08, 9:54AM CDT
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 12 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
CVS Health Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount
PR Newswire - Tue May 31, 7:00AM CDT
CVS Health Corporation ("CVS Health", NYSE: CVS) announced today the early tender results, applicable Reference Yields and consideration payable in connection with its previously announced cash tender offers (the "Tender Offers"
for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the "Any and All Notes" and (2) up to $1,500,000,000 aggregate principal amount of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.750% Senior Notes due 2041, the 5.00% Senior Notes due 2024 (the "Omnicare 2024 Notes" issued by its wholly-owned subsidiary, Omnicare, Inc. ("Omnicare", the 4.75% Senior Notes due 2022 (together with the Omnicare 2024 Notes, the "Omnicare Notes" issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Notes". OCR: 97.90 (-0.02), CVS: 95.78 (-0.89)
Global Intravenous Solutions Market Growth of 5.79% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Baxter, Terumo, Omnicare - Research and Markets
BusinessWire - Tue May 31, 3:58AM CDT
Research and Markets has announced the addition of the "Global Intravenous Solutions Market 2016-2020" report to their offering.
OCR: 97.90 (-0.02)
CVS Health Corporation Announces Cash Tender Offers for Certain Outstanding Notes
PR Newswire - Mon May 16, 7:45AM CDT
CVS Health Corporation ("CVS Health", NYSE: CVS) announced today that it has commenced cash tender offers (the "Tender Offers"
for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the "Any and All Notes" and (2) up to $1,500,000,000 aggregate principal amount (the "Maximum Tender Offer Amount" of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.750% Senior Notes due 2041, the 5.00% Senior Notes due 2024 (the "Omnicare 2024 Notes" issued by its wholly-owned subsidiary, Omnicare, Inc. ("Omnicare", the 4.75% Senior Notes due 2022 (the "Omnicare 2022 Notes", and together with the Omnicare 2024 Notes, the "Omnicare Notes" issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Notes". The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 16, 2016 (as amended or supplemented from time to time, the "Offer to Purchase" and related Letter of Transmittal (the "Letter of Transmittal". The Tender Offers are open to all registered holders (individually, a "Holder" and collectively, the "Holders" of the Notes. The purpose of the Tender Offers is to refinance a portion of CVS Health's outstanding indebtedness. OCR: 97.90 (-0.02), CVS: 95.78 (-0.89)
Ventas Board Appoints James D. Shelton as Presiding Director
BusinessWire - Tue May 10, 6:56PM CDT
Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company"
said today its Board of Directors (the "Board" has appointed James D. ("Denny" Shelton to serve as the Company's independent presiding director. Douglas Crocker II, who served the Company as independent presiding director for 13 years, has retired from the Board in connection with the Company's retirement policy. OCR: 97.90 (-0.02), EVHC: 27.18 (-0.47), VTR: 69.34 (+0.76)
Bass, Berry & Sims Releases Annual Review of 2015 Securities and Shareholder Litigation
BusinessWire - Thu Mar 10, 10:47AM CST
Bass, Berry & Sims PLC announces the release of the "Securities & Shareholder Litigation: 2015 Year-End Review," the firm's annual report on the most important trends and developments in securities and corporate governance matters affecting companies and their officers and directors. The report provides analysis of significant developments in corporate and securities law in 2015, including the establishment of the Tennessee Business Court, the new rulings applying the U.S. Supreme Court's Omnicare decision, merger and acquisition lawsuits and liability, and major cases out of the Sixth Circuit. Written with an eye to lawyers and non-lawyers alike, the report also offers practical guidance for officers, directors, and general counsel as they navigate these issues going forward. Download the full 2015 Securities and Shareholder Litigation Report here.
OCR: 97.90 (-0.02)
Fitch: Publix, AmerisourceBergen Deal Underscores Power of Scale
BusinessWire - Thu Feb 04, 12:51PM CST
The largest drug sourcing entities and major U.S. drug distributors continue to prove the benefits of their unmatched scale as they win increasingly comprehensive distribution contracts with pharmacy chains in the U.S., according to Fitch Ratings. This trend is highlighted by Thursday's announced agreement between AmerisourceBergen (ABC) and Publix.
ABC: 76.41 (-0.05), OCR: 97.90 (-0.02)
EXL Announces Appointment of Nitin Sahney to Board of Directors
GlobeNewswire - Tue Dec 15, 5:00AM CST
EXL (NASDAQ:EXLS), a leading business process solutions company, today announced that Nitin Sahney, the former President and CEO of Omnicare Inc. and a seasoned executive in the healthcare industry, has been appointed to the Company's Board of Directors as an independent director effective January 1, 2016. The appointment of Nitin Sahney follows the decision by Dr. Mohanbir Sawhney to retire from the Board of Directors effective December 31, 2015 following ten years of dedicated service.
EXLS: 51.30 (+0.01), OCR: 97.90 (-0.02)
RBNZ Cuts, But Could It Be the Last One?
Chuck Butler - Daily Reckoning - Thu Dec 10, 10:58AM CST
This post RBNZ Cuts, But Could It Be the Last One? appeared first on Daily Reckoning . The RBNZ cuts rates, while Governor Wheeler hints that this could be the last rate cut of this cycle. How are the currencies being affected? Chuck Butler...
OCR: 97.90 (-0.02), RBA: 33.42 (-0.08)
Omnicare Up 53.3% Since SmarTrend Uptrend Call (OCR)
Comtex SmarTrend(R) - Mon Nov 30, 10:21AM CST
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 14 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
Omnicare Has Returned 53.3% Since SmarTrend Recommendation (OCR)
Comtex SmarTrend(R) - Mon Nov 23, 9:22AM CST
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 13 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
Shares of OCR Up 53.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 13, 4:51PM CST
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 13 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
53.3% Return Seen to Date on SmarTrend Omnicare Call (OCR)
Comtex SmarTrend(R) - Fri Oct 30, 10:13AM CDT
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 12 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
Uptrend Call Working As Omnicare Stock Rises 53.3% (OCR)
Comtex SmarTrend(R) - Thu Oct 22, 4:44PM CDT
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 12 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
The ECB, and Draghi Have the Spotlight
Chuck Butler - Daily Reckoning - Thu Oct 22, 9:24AM CDT
This post The ECB, and Draghi Have the Spotlight appeared first on Daily Reckoning . The markets have fired a warning shot across the ECB's bow, and threatened to push the euro higher if the ECB doesn't add more stimulus. Oh the Humanity! Chuck...
OCR: 97.90 (-0.02), BOE: 11.77 (-0.37)
CVS Health Corporation Announces Expiration of Exchange Offers and Consent Solicitations
PR Newswire - Wed Oct 21, 9:55AM CDT
CVS Health Corporation ("CVS Health", NYSE: CVS) announced today the expiration at 11:59 p.m., New York City time, on October 20, 2015 (the "Expiration Date"
, of its previously announced (A) private exchange offers ("Exchange Offers" to Eligible Holders (as defined below) to exchange new 4.75% Senior Notes due 2022 (the "New CVS Health 2022 Notes" and new 5.00% Senior Notes due 2024 (the "New CVS Health 2024 Notes" and, together with the New CVS Health 2022 Notes, the "New CVS Health Notes", in each case issued by CVS Health, and cash payments for the 4.75% Senior Notes due 2022 (the "Existing Omnicare 2022 Notes" and the 5.00% Senior Notes due 2024 (the "Existing Omnicare 2024 Notes" and, together with the Existing Omnicare 2022 Notes, the "Existing Omnicare Notes", in each case issued by Omnicare, Inc. ("Omnicare", which was recently acquired by CVS Health, and ( solicitation of consents (the "Consent Solicitations" from Eligible Holders of Existing Omnicare Notes to proposed amendments that would eliminate substantially all restrictive covenants and certain events of default and other provisions of the indentures under which such Existing Omnicare Notes were issued (the "Proposed Amendments". OCR: 97.90 (-0.02), CVS: 95.78 (-0.89)
Tailwind Capital Expands its Healthcare Team
BusinessWire - Wed Oct 21, 7:00AM CDT
Tailwind Capital, a leading middle market private equity firm investing in growth-oriented companies in targeted sectors in healthcare, business and communications services, announced that it has recently added Eran Broshy and Cliff Gookin as Operating Executives.
OCR: 97.90 (-0.02)
Omnicare Shares Up 53.3% Since SmarTrend's Buy Recommendation (OCR)
Comtex SmarTrend(R) - Thu Oct 08, 9:54AM CDT
SmarTrend identified an Uptrend for Omnicare (NYSE:OCR) on October 21st, 2014 at $63.85. In approximately 12 months, Omnicare has returned 53.33% as of today's recent price of $97.90.
OCR: 97.90 (-0.02)
